Halt Medical

A key feature of the Acessa procedure is its use of simultaneous laparoscopic and ultrasound guidance. This dual-visualization allows surgeons to locate and treat a wide range of fibroid types and sizes, even those that might be missed by MRI or transvaginal ultrasound alone. The procedure is performed through small abdominal incisions, preserving the uterus and avoiding the need for tissue removal or morcellation. This approach targets only the fibroids, leaving healthy uterine tissue unaffected. Patients typically experience a rapid recovery, returning to normal activities within four to five days.

The company's business model centered on the sale of the Acessa System to hospitals and medical centers. A significant milestone was achieved in November 2012 when the Acessa system received FDA clearance for the treatment of uterine fibroids. This was followed by a 510(k) clearance from the FDA in 2014 for its advanced guidance handpiece. The system also secured regulatory approvals in the European Union, Canada, and Mexico. In April 2017, Halt Medical filed for Chapter 11 bankruptcy protection and entered into an asset purchase agreement with Acessa Health, Inc., to ensure the continued operation and availability of the Acessa procedure. Later, in August 2020, Halt Medical was acquired by Hologic for an estimated $80 million.